Huang Guo, Wei Xuefeng, Tang Huiqin, Bai Fei, Lin Xia, Xue Di
NHC Key Laboratory of Health Technology Assessment (Fudan University), Department of Hospital Management, School of Public Health, Fudan University, Shanghai, China.
Health Commission of Gansu Province, Lanzhou, China.
J Thorac Dis. 2021 Aug;13(8):4797-4811. doi: 10.21037/jtd-21-810.
Lung cancer was the second most commonly diagnosed cancer and the leading cause of cancer death in 2020. Although artificial intelligence (AI)-assisted diagnostic technologies have shown promise and has been used in clinical practice in recent years, no products related to AI-assisted CT diagnostic technologies for the classification of pulmonary nodules have been approved by the National Medical Products Administration in China. The objective of this article was to systematically review the diagnostic performance of AI-assisted CT diagnostic technology for the classification of pulmonary nodules as benign or malignant and to analyze physicians' perceptions of this technology in China.
All relevant studies from 6 literature databases were searched and screened according to the inclusion and exclusion criteria. Data were extracted and the study quality was assessed by two reviewers. The study heterogeneity and publication bias were estimated. A questionnaire survey on the perceptions of physicians was conducted in 9 public tertiary hospitals in China. A meta-analysis, meta-regression and univariate logistic model were used in the systematic review and to explore the association of physicians' perceptions with their rate of support for the clinical application of the technology.
Twenty-seven studies with 5,727 pulmonary nodules were finally included in the meta-analysis. We found that the quality of the included studies was generally acceptable and that the pooled sensitivity and specificity of AI-assisted CT diagnostic technology for the classification of pulmonary nodules as benign or malignant were 0.90 and 0.89, respectively. The pooled diagnostic odds ratio (DOR) was 70.33. The majority of the surveyed physicians in China perceived "reduced workload for radiologists" and "improved diagnostic efficiency" as the important benefits of this technology. In addition, diagnostic accuracy (including misdiagnosis) and practical experience were significantly associated with whether physicians supported its clinical application.
In the context of lung cancer diagnosis, AI-assisted CT diagnostic technology for the classification of pulmonary nodules as benign or malignant has good diagnostic performance, but its specificity needs to be improved.
肺癌是2020年第二大最常被诊断出的癌症,也是癌症死亡的主要原因。尽管近年来人工智能(AI)辅助诊断技术已显示出前景并已应用于临床实践,但中国国家药品监督管理局尚未批准任何与用于肺结节分类的AI辅助CT诊断技术相关的产品。本文的目的是系统评价AI辅助CT诊断技术对肺结节良恶性分类的诊断性能,并分析中国医生对该技术的看法。
根据纳入和排除标准,检索并筛选了6个文献数据库中的所有相关研究。由两名审阅者提取数据并评估研究质量。估计研究异质性和发表偏倚。在中国9家公立三级医院对医生的看法进行了问卷调查。在系统评价中使用了荟萃分析、荟萃回归和单变量逻辑模型,以探讨医生的看法与其对该技术临床应用的支持率之间的关联。
荟萃分析最终纳入了27项研究,共5727个肺结节。我们发现纳入研究的质量总体上可以接受,AI辅助CT诊断技术对肺结节良恶性分类的合并敏感性和特异性分别为0.90和0.89。合并诊断比值比(DOR)为70.33。中国大多数接受调查的医生认为“减少放射科医生的工作量”和“提高诊断效率”是该技术的重要益处。此外,诊断准确性(包括误诊)和实践经验与医生是否支持其临床应用显著相关。
在肺癌诊断的背景下,用于肺结节良恶性分类的AI辅助CT诊断技术具有良好的诊断性能,但其特异性有待提高。